StreetInsider.com News Articles

Puma Biotechnology (PBYI) PT Raised to $6 at TD Cowen

Fri, 07 Aug 2026 08:52:27 -0400

TD Cowen analyst Marc Frahm raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $6.00 (from $5.00) while maintaining a Hold rating.

Puma Biotech (PBYI) Tops Q2 EPS by 16c

Thu, 06 Aug 2026 17:45:52 -0400

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $56.5 million versus the consensus estimate of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Jun 30

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884993.html

Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Jun 30

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884993.html

Form 8-K PUMA BIOTECHNOLOGY, INC. For: Aug 06

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884439.html

Form 8-K PUMA BIOTECHNOLOGY, INC. For: Aug 06

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884439.html

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for the second quarter 2026 compared to the second quarter 2025.

Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the second quarter of 2026 was $53.6 million, compared to product revenue, net of $49.2 million in the second quarter of 2025. Product revenue, net in the

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to five new non-executive employees.

The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: AUERBACH ALAN H

Wed, 08 Jul 2026 20:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748765.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: AUERBACH ALAN H

Wed, 08 Jul 2026 20:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748765.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: HUNT DOUGLAS M

Wed, 08 Jul 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260708/26748760.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: HUNT DOUGLAS M

Wed, 08 Jul 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260708/26748760.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: NOUGUES MAXIMO F

Wed, 08 Jul 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260708/26748753.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Jul 06 Filed by: NOUGUES MAXIMO F

Wed, 08 Jul 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260708/26748753.html

Form 144 PUMA BIOTECHNOLOGY, INC. Filed by: AUERBACH ALAN H

Mon, 06 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260706/26736364.html